UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: results from the FIRST registry
V Speed, JP Patel, LN Roberts… - Thrombosis …, 2021 - thrombosisresearch.com
1. Background The treatment of acute venous thromboembolism (VTE) in patients with
bodyweight> 120 kg or BMI> 40 kg/m 2 with a direct oral anticoagulant (DOAC) is …
bodyweight> 120 kg or BMI> 40 kg/m 2 with a direct oral anticoagulant (DOAC) is …
Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation
K Kido, S Ngorsuraches - Annals of Pharmacotherapy, 2019 - journals.sagepub.com
Background: The International Society of Thrombosis and Haemostasis recommends
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …
[HTML][HTML] Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study
Background Due to a paucity of data on the efficacy and safety of direct oral anticoagulants
(DOACs) in patients with a body mass index> 40 kg/m 2 or a weight> 120 kg, the use of …
(DOACs) in patients with a body mass index> 40 kg/m 2 or a weight> 120 kg, the use of …
Treatment of Atrial Fibrillation and Venous Thromboembolism with Factor Xa Inhibitors in Severely Obese Patients
Background A paucity of data exists to support the use of factor Xa inhibitors in severely
obese patients with a weight≥ 150kg or BMI≥ 50 kg/m 2. Objectives The purpose of this …
obese patients with a weight≥ 150kg or BMI≥ 50 kg/m 2. Objectives The purpose of this …
Impact of BMI on clinical outcomes of NOAC therapy in daily care-Results of the prospective Dresden NOAC Registry (NCT01588119)
L Tittl, S Endig, S Marten, A Reitter… - International journal of …, 2018 - Elsevier
Direct acting non-Vitamin K antagonist oral anticoagulants (NOAC) are characterized by a
fixed dosing regimen. Despite the potential for relative underdosing due to large distribution …
fixed dosing regimen. Despite the potential for relative underdosing due to large distribution …
Management of venous thromboembolism in morbidly obese patients: A 10-year review
B Wee, B Lui, J Lai, Z Khattak, A Kwok… - Journal of Thrombosis …, 2023 - Springer
Obesity is a known risk factor for venous thromboembolism (VTE) and poses a unique set of
challenges in anticoagulation management. We report a 10-year experience of VTE …
challenges in anticoagulation management. We report a 10-year experience of VTE …
Comparative effectiveness and safety of direct oral anticoagulants in obese patients with atrial fibrillation
Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …
Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of …
MND Di Minno, R Lupoli, A Di Minno… - Annals of …, 2015 - Taylor & Francis
Objective. To evaluate the effect of body weight (BW) on safety and efficacy of direct oral
anticoagulants (DOACs). Methods. We performed a meta-analysis of randomized controlled …
anticoagulants (DOACs). Methods. We performed a meta-analysis of randomized controlled …
Direct oral anticoagulants in patients with obesity and atrial fibrillation: position paper of Italian National Association of Hospital Cardiologists (ANMCO)
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …
Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous …
H Zhang, H Xie, X Wang, Z Zhu, F Duan - Medicine, 2023 - journals.lww.com
Background: Venous thromboembolism (VTE) poses a significant health risk to patients with
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …